^
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
01/26/2022
Initiation :
09/12/2017
Primary completion :
04/02/2024
Completion :
04/02/2024
MSI • MLH1 • MSH6 • MSH2 • CD4
|
MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation • MSH6 expression
|
Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • fluorouracil topical
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
01/26/2022
Initiation :
10/05/2021
Primary completion :
08/14/2023
Completion :
08/14/2024
PD-L1 • CD4
|
PD-L1 negative
|
entinostat (SNDX-275) • bintrafusp alfa (M7824) • M-9241
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
01/26/2022
Initiation :
02/01/2016
Primary completion :
11/08/2018
CD4
|
ropidoxuridine (IPdR)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
01/26/2022
Initiation :
11/07/2017
Primary completion :
04/30/2022
Completion :
04/30/2022
BRAF • MSI • MLH1 • MSH6 • MSH2
|
BRAF V600E • MSI-H/dMMR • BRAF V600
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • leucovorin calcium • Krabeva (bevacizumab biosimilar) • fluorouracil topical • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 1b/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/25/2022
Initiation :
12/02/2020
Primary completion :
12/31/2022
Completion :
12/31/2022
BRAF • KRAS • MAP2K1
|
Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • KL 140 (cetuximab biosimilar)
Phase 3
GERCOR - Multidisciplinary Oncology Cooperative...
Active, not recruiting
Last update posted :
01/25/2022
Initiation :
05/12/2009
Primary completion :
01/01/2020
Completion :
03/01/2022
CEACAM5
|
5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
Phase 2
AIO-Studien-gGmbH
Recruiting
Last update posted :
01/25/2022
Initiation :
12/10/2021
Primary completion :
11/15/2026
Completion :
11/15/2026
MSI
|
MSI-H/dMMR
|
Tecentriq (atezolizumab) • oxaliplatin • IMM-101
Phase 3
Swiss Group for Clinical Cancer Research
Active, not recruiting
Last update posted :
01/21/2022
Initiation :
06/09/2016
Primary completion :
06/01/2029
Completion :
06/01/2029
PIK3CA
|
PIK3CA mutation
|
aspirin
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
01/20/2022
Initiation :
12/05/2007
Primary completion :
06/30/2022
Completion :
06/30/2022
BRCA
|
irinotecan • veliparib (ABT-888)
Phase 1
HUYABIO International, LLC.
Recruiting
Last update posted :
01/20/2022
Initiation :
12/13/2021
Primary completion :
12/01/2024
Completion :
12/01/2024
EGFR • KRAS
|
KRAS mutation • EGFR mutation
|
HBI-2376
Phase N/A
University of Wisconsin, Madison
Recruiting
Last update posted :
01/19/2022
Initiation :
01/01/2022
Primary completion :
12/01/2030
Completion :
12/01/2030
CEACAM5
Phase 2
University College, London
Not yet recruiting
Last update posted :
01/19/2022
Initiation :
03/01/2022
Primary completion :
08/01/2024
Completion :
03/01/2027
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
Phase N/A
Azienda Ospedaliero-Universitaria di Modena
Recruiting
Last update posted :
01/19/2022
Initiation :
01/01/2022
Primary completion :
01/01/2027
Completion :
01/01/2032
CEACAM5
|
BRAF wild-type
Phase 1/2
Loxo Oncology, Inc.
Recruiting
Last update posted :
01/19/2022
Initiation :
05/02/2017
Primary completion :
11/21/2022
Completion :
11/21/2023
RET
|
Retevmo (selpercatinib)
Phase 3
Sun Yat-sen University
Recruiting
Last update posted :
01/17/2022
Initiation :
12/01/2021
Primary completion :
12/01/2024
Completion :
12/01/2026
MSI
|
MSI-H/dMMR
|
5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
Academic and Community Cancer Research United
Active, not recruiting
Last update posted :
01/14/2022
Initiation :
03/27/2015
Primary completion :
09/01/2017
Completion :
06/07/2025
KRAS
|
RAS wild-type • KRAS wild-type
|
Stivarga (regorafenib) • clobetasol propionate topical
Phase 1
Novartis Pharmaceuticals
Recruiting
Last update posted :
01/13/2022
Initiation :
07/22/2020
Primary completion :
08/17/2023
Completion :
08/17/2023
BRAF • DUSP6
|
BRAF mutation • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • spartalizumab (PDR001) • naporafenib (LXH254) • rineterkib (LTT462) • TNO-155
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
01/13/2022
Initiation :
03/07/2018
Primary completion :
11/01/2022
Completion :
11/01/2022
BRAF • MSI
|
bintrafusp alfa (M7824)
Phase 2
Bayer
Active, not recruiting
Last update posted :
01/13/2022
Initiation :
10/14/2019
Primary completion :
11/11/2020
Completion :
05/03/2022
EGFR
|
RAS wild-type
|
Opdivo (nivolumab) • Stivarga (regorafenib)
Phase 1/2
Elucida Oncology
Recruiting
Last update posted :
01/12/2022
Initiation :
09/13/2021
Primary completion :
03/15/2024
Completion :
03/15/2025
FOLR1
|
ELU001
Phase 2
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
01/11/2022
Initiation :
03/12/2014
Primary completion :
03/14/2023
Completion :
03/14/2024
MSI
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cotellic (cobimetinib) • Darzalex IV (daratumumab) • relatlimab (BMS-986016)
Phase 2
SCRI Development Innovations, LLC
Completed
Last update posted :
01/11/2022
Initiation :
07/01/2005
Primary completion :
06/01/2008
Completion :
07/01/2010
EGFR
|
Erbitux (cetuximab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
01/11/2022
Initiation :
08/28/2017
Primary completion :
03/31/2022
Completion :
06/17/2022
EGFR • BRAF
|
BRAF V600E • EGFR mutation • EGFR T790M
|
spartalizumab (PDR001) • taminadenant (NIR178)
Phase 2
Seagen Inc.
Active, not recruiting
Last update posted :
01/11/2022
Initiation :
06/23/2017
Primary completion :
05/31/2022
Completion :
04/30/2023
HER-2
|
HER-2 positive • MSI-H/dMMR • HER-2 amplification • HER-2 overexpression • RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
Phase 2
UNICANCER
Completed
Last update posted :
01/11/2022
Initiation :
12/01/2010
Primary completion :
10/01/2015
Completion :
12/31/2017
KRAS
|
KRAS wild-type • KRAS expression
|
Erbitux (cetuximab) • Avastin (bevacizumab) • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
01/11/2022
Initiation :
01/30/2019
Primary completion :
01/31/2022
Completion :
01/31/2022
BRAF • KRAS • MET • MSI
|
MET amplification • KRAS wild-type • NRAS wild-type
|
Orpathys (savolitinib)
Phase 1
Exelixis
Recruiting
Last update posted :
01/07/2022
Initiation :
03/20/2019
Primary completion :
11/01/2023
Completion :
11/01/2024
HER-2 • PD-L1
|
HR positive
|
Tecentriq (atezolizumab) • Bavencio (avelumab) • XL092
Phase 2
Southwest Oncology Group
Recruiting
Last update posted :
01/07/2022
Initiation :
10/09/2017
Primary completion :
11/01/2022
Completion :
06/15/2023
EGFR • HER-2 • BRAF • KRAS • NRAS
|
BRAF V600E • HER-2 amplification • BRAF V600 • KRAS exon 4 mutation • BRAF exon 15 mutation
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan
Phase 1
Emory University
Active, not recruiting
Last update posted :
01/06/2022
Initiation :
12/15/2017
Primary completion :
12/31/2022
Completion :
12/31/2022
CD8
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • pepinemab (VX15)
Phase 2/3
NRG Oncology
Not yet recruiting
Last update posted :
12/30/2021
Initiation :
01/11/2022
Primary completion :
01/11/2029
Completion :
01/11/2030
MSI
|
capecitabine • oxaliplatin • irinotecan
Phase 1/2
Karyopharm Therapeutics Inc
Recruiting
Last update posted :
12/30/2021
Initiation :
01/01/2016
Primary completion :
08/31/2024
Completion :
08/31/2024
KRAS
|
RAS wild-type • KRAS wild-type
|
abiraterone acetate • dexamethasone • Inqovi (decitabine/cedazuridine) • eltanexor (KPT-8602)
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Active, not recruiting
Last update posted :
12/29/2021
Initiation :
10/23/2018
Primary completion :
09/01/2021
Completion :
10/01/2022
KRAS
|
RAS wild-type
|
Opdivo (nivolumab) • Stivarga (regorafenib)
Phase 3
G1 Therapeutics, Inc.
Recruiting
Last update posted :
12/24/2021
Initiation :
10/16/2020
Primary completion :
11/25/2022
Completion :
11/30/2024
BRAF • KRAS
|
KRAS mutation • BRAF mutation
|
Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium • Cosela (trilaciclib)
Phase 2
University of Florida
Recruiting
Last update posted :
12/24/2021
Initiation :
11/04/2021
Primary completion :
05/01/2024
Completion :
05/01/2025
BRAF • MSI • UGT1A1
|
UGT1A1*28 • UGT1A1*1*1
Phase 2
University of Rochester
Recruiting
Last update posted :
12/22/2021
Initiation :
03/15/2021
Primary completion :
12/31/2023
Completion :
12/31/2023
IL6 • TNFA • IL1B
Phase 1a/1b
Genentech, Inc.
Recruiting
Last update posted :
12/21/2021
Initiation :
12/21/2017
Primary completion :
02/01/2024
Completion :
02/01/2024
HER-2 • ER • PGR
|
HER-2 negative • PGR negative
|
Tecentriq (atezolizumab) • autogene cevumeran (RG6180)
Phase 
Gritstone Oncology, Inc.
Recruiting
Last update posted :
12/15/2021
Initiation :
09/17/2021
Primary completion :
05/01/2022
Completion :
07/01/2022
KRAS
Phase 1
Mirati Therapeutics Inc.
Recruiting
Last update posted :
12/13/2021
Initiation :
08/12/2021
Primary completion :
11/30/2023
Completion :
02/28/2024
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
adagrasib (MRTX849) • BI 1701963
Phase 3
Institut du Cancer de Montpellier - Val d'Aurelle
Recruiting
Last update posted :
12/13/2021
Initiation :
03/28/2019
Primary completion :
08/01/2023
Completion :
08/01/2023
CCND1
|
RAS wild-type
|
irinotecan • Stivarga (regorafenib)
Phase 1/2
Hoffmann-La Roche
Recruiting
Last update posted :
12/09/2021
Initiation :
03/17/2017
Primary completion :
12/31/2021
Completion :
02/29/2024
RET • CEACAM5
|
RET fusion • RET mutation • RET rearrangement
|
Gavreto (pralsetinib)
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
12/07/2021
Initiation :
03/29/2021
Primary completion :
01/11/2024
Completion :
01/11/2024
EGFR • BRAF • KRAS • MSI
|
BRAF V600E • MSI-H/dMMR • BRAF V600 • RAS wild-type • KRAS wild-type • NRAS wild-type
|
Keytruda (pembrolizumab) • lenvatinib • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
Phase 3
Federation Francophone de Cancerologie Digestive
Completed
Last update posted :
12/07/2021
Initiation :
09/01/2009
Primary completion :
12/01/2019
Completion :
06/01/2021
CEACAM5
Phase 3
Ludwig-Maximilians - University of Munich
Recruiting
Last update posted :
12/03/2021
Initiation :
03/01/2015
Primary completion :
12/01/2022
Completion :
12/01/2024
KRAS
|
KRAS exon 2 mutation • RAS wild-type • KRAS wild-type • KRAS exon 2 wild-type • NRAS wild-type
|
Erbitux (cetuximab) • Avastin (bevacizumab) • 5-fluorouracil • capecitabine • irinotecan • Stivarga (regorafenib) • leucovorin calcium
Phase 2
Ludwig-Maximilians - University of Munich
Active, not recruiting
Last update posted :
12/03/2021
Initiation :
11/25/2016
Primary completion :
11/01/2022
Completion :
12/31/2023
BRAF • KRAS
|
BRAF V600E • BRAF V600 • KRAS exon 2 mutation • RAS wild-type • KRAS wild-type • KRAS exon 2 wild-type
|
Erbitux (cetuximab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
University of Colorado, Denver
Recruiting
Last update posted :
12/02/2021
Initiation :
06/23/2021
Primary completion :
02/09/2024
Completion :
02/09/2025
BRAF • MSI
|
RAS wild-type
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
Phase N/A
UConn Health
Completed
Last update posted :
11/25/2021
Initiation :
05/20/2019
Primary completion :
04/08/2021
Completion :
04/08/2021
TIMP1
Phase 1b/2a
Anup Kasi
Recruiting
Last update posted :
11/24/2021
Initiation :
10/20/2021
Primary completion :
09/01/2023
Completion :
09/01/2025
BRAF
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CEND-1
Phase 1
Jonsson Comprehensive Cancer Center
Recruiting
Last update posted :
11/23/2021
Initiation :
11/05/2019
Primary completion :
06/01/2030
Completion :
10/17/2031
FOLH1 • FAP
|
FOLH1 expression
|
FAPI-46
Phase 1/2
Chandrikha Chandrasekharan
Recruiting
Last update posted :
11/23/2021
Initiation :
10/05/2020
Primary completion :
10/01/2022
Completion :
10/01/2022
MSI
|
MSI-H/dMMR • RAS wild-type
|
Imfinzi (durvalumab)
Phase 1
Fudan University
Recruiting
Last update posted :
11/23/2021
Initiation :
03/01/2021
Primary completion :
12/01/2022
Completion :
12/01/2023
NKG2D
|
KD-025 CAR T-cells
Phase 3
Taizhou Mabtech Pharmaceutical Co.,Ltd
Active, not recruiting
Last update posted :
11/19/2021
Initiation :
12/12/2017
Primary completion :
03/31/2022
Completion :
06/30/2022
BRAF
|
BRAF wild-type
|
5-fluorouracil • irinotecan • leucovorin calcium • fluorouracil topical • CMAB009 (cetuximab biosimilar)
Phase 2
Massachusetts General Hospital
Withdrawn
Last update posted :
11/17/2021
Initiation :
11/30/2019
Primary completion :
11/30/2021
Completion :
11/30/2021
PD-L1 • CD8 • IL6 • PD-1 • LAG3 • TNFA • HAVCR2 • CTLA4 • TIGIT • CCL2 • IL10 • FOXP3
|
icosapent ethyl
Phase N/A
Geisinger Clinic
Withdrawn
Last update posted :
11/17/2021
Initiation :
11/01/2021
Primary completion :
05/01/2022
Completion :
09/01/2022
MSH2
Phase 1
George E. Peoples
Recruiting
Last update posted :
11/16/2021
Initiation :
07/20/2019
Primary completion :
12/20/2021
Completion :
05/20/2022
PD-L1 • CD4
|
PD-L1 expression
Phase 2
Academic and Community Cancer Research United
Recruiting
Last update posted :
11/16/2021
Initiation :
04/24/2020
Primary completion :
12/31/2022
Completion :
10/07/2023
BRAF • KRAS • MSI
|
MSI-H/dMMR • KRAS wild-type • NRAS wild-type
|
Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
Phase N/A
University of Rochester
Recruiting
Last update posted :
11/15/2021
Initiation :
03/01/2016
Primary completion :
03/01/2022
Completion :
04/01/2022
IL6 • IL10 • IL1B
Phase 1/2
Cantargia AB
Recruiting
Last update posted :
11/11/2021
Initiation :
09/22/2021
Primary completion :
09/08/2023
Completion :
09/06/2024
PD-L1 • KRAS • MSI • PD-1 • CD4
|
MSI-H/dMMR • RAS wild-type • KRAS wild-type
|
cisplatin • gemcitabine • 5-fluorouracil • docetaxel • oxaliplatin • leucovorin calcium • nadunolimab (CAN04)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Active, not recruiting
Last update posted :
11/11/2021
Initiation :
03/09/2018
Primary completion :
09/21/2020
Completion :
03/31/2024
BRAF • KRAS • MLH1 • MSH6 • MSH2
|
KRAS wild-type • NRAS wild-type
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Vectibix (panitumumab)
Phase 1/2
Hutchison Medipharma Limited
Recruiting
Last update posted :
11/03/2021
Initiation :
03/05/2021
Primary completion :
02/27/2023
Completion :
04/30/2023
BRAF • PD-L1
|
BRAF V600E • BRAF V600
|
Baize’an (tislelizumab) • Sulanda (surufatinib)
Phase N/A
University Medicine Greifswald
Recruiting
Last update posted :
11/02/2021
Initiation :
06/25/2020
Primary completion :
09/30/2022
Completion :
09/30/2022
CRP
Phase 2
London North West Healthcare NHS Trust
Active, not recruiting
Last update posted :
10/29/2021
Initiation :
04/14/2019
Primary completion :
03/06/2021
Completion :
03/01/2026
CRP
Phase 1
Pravin Kaumaya
Recruiting
Last update posted :
10/27/2021
Initiation :
06/21/2011
Primary completion :
12/31/2022
Completion :
12/31/2022
EGFR • HER-2
|
HER-2 overexpression • HER-2 expression • EGFR expression
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/26/2021
Initiation :
08/04/2005
Primary completion :
02/01/2022
Completion :
02/01/2022
MSI • MSH2
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • leucovorin calcium • Krabeva (bevacizumab biosimilar) • fluorouracil topical • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase N/A
Academic and Community Cancer Research United
Recruiting
Last update posted :
10/25/2021
Initiation :
04/20/2020
Primary completion :
11/12/2023
Completion :
11/12/2025
HER-2 • KRAS • NRAS • MSI
|
MSI-H/dMMR • HER-2 amplification • HER-2 expression • RAS wild-type • KRAS wild-type • NRAS wild-type
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/18/2021
Initiation :
03/05/2021
Primary completion :
03/31/2026
Completion :
03/31/2026
CD4
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
Phase 2
TheraOp
Active, not recruiting
Last update posted :
10/15/2021
Initiation :
12/29/2020
Primary completion :
07/22/2024
Completion :
10/01/2024
KRAS • NRAS
|
KRAS mutation • KRAS exon 2 mutation • RAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/13/2021
Initiation :
09/24/2021
Primary completion :
03/31/2024
Completion :
03/31/2024
TP53 • TMB • CASP3
|
TP53 mutation • TP53 wild-type
|
atorvastatin
Phase N/A
Assistance Publique - Hôpitaux de Paris
Active, not recruiting
Last update posted :
10/12/2021
Initiation :
03/11/2015
Primary completion :
12/31/2021
Completion :
12/31/2021
BRAF
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/06/2021
Initiation :
06/14/2019
Primary completion :
06/30/2024
Completion :
06/30/2025
BRAF
|
BRAF V600E • BRAF V600
|
Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • KL 140 (cetuximab biosimilar)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Recruiting
Last update posted :
10/06/2021
Initiation :
03/13/2018
Primary completion :
01/13/2023
Completion :
01/13/2026
BRAF • KRAS • NRAS
|
KRAS wild-type • BRAF wild-type • NRAS wild-type
|
Erbitux (cetuximab) • Ibrance (palbociclib)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Active, not recruiting
Last update posted :
10/06/2021
Initiation :
05/01/2014
Primary completion :
05/01/2022
Completion :
05/01/2023
UGT1A1
|
UGT1A1*1*1
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Mvasi (bevacizumab biosimilar) • leucovorin calcium
Phase 3
University of Auckland, New Zealand
Completed
Last update posted :
09/29/2021
Initiation :
10/25/2017
Primary completion :
08/30/2020
Completion :
08/30/2020
IL6 • TNFA • IL1B
|
Resolor (prucalopride)
Phase N/A
University of Leeds
Recruiting
Last update posted :
09/28/2021
Initiation :
09/16/2021
Primary completion :
07/01/2024
Completion :
07/01/2025
PD-1 • HAVCR2 • CTLA4 • TIGIT • CCL2
|
icosapent ethyl
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Active, not recruiting
Last update posted :
09/24/2021
Initiation :
03/25/2019
Primary completion :
09/30/2021
Completion :
02/01/2022
MGMT
|
MGMT promoter methylation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide
Phase N/A
Hospital Universitario de Móstoles
Recruiting
Last update posted :
09/23/2021
Initiation :
06/05/2021
Primary completion :
05/01/2023
Completion :
11/01/2023
BRAF • KRAS
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
10/27/2017
Primary completion :
02/23/2020
Completion :
09/28/2021
EGFR • APC
|
EGFR expression • APC mutation
|
erlotinib
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Active, not recruiting
Last update posted :
09/16/2021
Initiation :
09/10/2012
Primary completion :
03/01/2022
Completion :
03/01/2022
MSI • CHFR
|
gemcitabine • docetaxel • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
Phase N/A
Pennington Biomedical Research Center
Recruiting
Last update posted :
09/15/2021
Initiation :
08/16/2019
Primary completion :
07/30/2022
Completion :
07/31/2023
IL6 • TNFA • CRP
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
09/13/2021
Initiation :
03/21/2018
Primary completion :
11/01/2021
Completion :
11/01/2021
KRAS
|
Mekinist (trametinib) • Imfinzi (durvalumab)
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Not yet recruiting
Last update posted :
09/10/2021
Initiation :
11/01/2021
Primary completion :
11/01/2024
Completion :
11/01/2024
MGMT • CEACAM5
|
MGMT promoter methylation
|
temozolomide • irinotecan
Phase N/A
University of Southern Denmark
Recruiting
Last update posted :
09/10/2021
Initiation :
09/02/2020
Primary completion :
09/30/2022
Completion :
08/31/2025
CRP
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Completed
Last update posted :
09/09/2021
Initiation :
09/01/2014
Primary completion :
07/30/2019
Completion :
07/30/2019
KRAS • MGMT
|
MGMT promoter methylation
|
5-fluorouracil • temozolomide • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
UNICANCER
Recruiting
Last update posted :
09/06/2021
Initiation :
11/23/2020
Primary completion :
11/23/2023
Completion :
05/23/2028
EGFR
|
Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
09/02/2021
Initiation :
05/27/2020
Primary completion :
12/31/2021
Completion :
12/31/2021
BRAF
|
BRAF wild-type
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Stivarga (regorafenib)
Phase 1/2
Klus Pharma Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
07/16/2018
Primary completion :
04/01/2022
Completion :
12/01/2022
HER-2
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
Phase 1
Hutchison Medipharma Limited
Recruiting
Last update posted :
08/31/2021
Initiation :
11/10/2017
Primary completion :
12/15/2021
Completion :
06/30/2022
HER-2
|
HR positive • HER-2 negative • RAS wild-type
|
Elunate (fruquintinib)
Phase 3
Hutchison Medipharma Limited
Recruiting
Last update posted :
08/31/2021
Initiation :
07/10/2020
Primary completion :
03/01/2022
Completion :
07/01/2022
MSI
|
RAS wild-type
|
Elunate (fruquintinib)
Phase N/A
Rutgers, The State University of New Jersey
Recruiting
Last update posted :
08/30/2021
Initiation :
09/01/2017
Primary completion :
08/31/2021
Completion :
08/31/2021
NFKB1
Phase 2
Massachusetts General Hospital
Active, not recruiting
Last update posted :
08/26/2021
Initiation :
10/31/2017
Primary completion :
03/26/2020
Completion :
11/30/2024
TP53
|
TP53 mutation • RAS wild-type
|
lamivudine • lamivudine/zidovudine
Phase 3
GCS IHFB Cognacq-Jay
Recruiting
Last update posted :
08/26/2021
Initiation :
09/02/2020
Primary completion :
10/01/2022
Completion :
08/01/2023
KDR • FLT4 • VEGFC
|
5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)
Phase N/A
Hospital Universitario La Fe
Active, not recruiting
Last update posted :
08/26/2021
Initiation :
06/01/2017
Primary completion :
01/01/2027
Completion :
01/01/2027
BRAF
Phase N/A
Herlev and Gentofte Hospital
Recruiting
Last update posted :
08/25/2021
Initiation :
02/21/2019
Primary completion :
02/01/2022
Completion :
02/01/2025
IL6 • GDF15 • CHI3L1 • CRP
Phase 2
Dominik Paul Modest
Not yet recruiting
Last update posted :
08/20/2021
Initiation :
10/01/2021
Primary completion :
12/01/2029
Completion :
12/01/2032
KRAS • NRAS
|
KRAS exon 2 mutation • RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab) • Lonsurf (trifluridine/tipiracil)
Phase N/A
University Hospital Dubrava
Completed
Last update posted :
08/20/2021
Initiation :
01/28/2019
Primary completion :
06/12/2021
Completion :
06/18/2021
IL6
|
ketamine
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
08/20/2021
Initiation :
01/17/2019
Primary completion :
01/01/2022
Completion :
01/01/2022
BRAF • KRAS
|
KRAS wild-type • BRAF wild-type • NRAS wild-type
|
Opdivo (nivolumab) • Aliqopa (copanlisib)
Phase N/A
East Lancashire Hospitals NHS Trust
Recruiting
Last update posted :
08/17/2021
Initiation :
07/15/2021
Primary completion :
04/01/2022
Completion :
04/01/2022
IL6 • IL10
Phase 1b
Celyad Oncology SA
Not yet recruiting
Last update posted :
08/05/2021
Initiation :
11/15/2021
Primary completion :
08/21/2023
Completion :
05/25/2038
MSI
|
Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • CYAD-101
Phase 1/2
Peking University
Recruiting
Last update posted :
08/03/2021
Initiation :
12/24/2020
Primary completion :
06/24/2023
Completion :
12/24/2023
MSI
|
MSI-H/dMMR
|
Avastin (bevacizumab) • Tuoyi (toripalimab) • irinotecan
Phase 1
University of California, San Francisco
Active, not recruiting
Last update posted :
07/29/2021
Initiation :
01/09/2017
Primary completion :
05/20/2021
Completion :
02/28/2025
CEACAM5
|
Lonsurf (trifluridine/tipiracil)
Phase 1/2
Asha Nayak
Recruiting
Last update posted :
07/29/2021
Initiation :
01/10/2018
Primary completion :
12/01/2022
Completion :
12/01/2022
PD-L1
|
Keytruda (pembrolizumab) • Hiltonol (poly-ICLC)
Phase 1
David Wald
Active, not recruiting
Last update posted :
07/27/2021
Initiation :
05/22/2018
Primary completion :
06/01/2021
Completion :
05/01/2022
NCAM1
|
Anktiva (inbakicept)
Phase 1
University of Rome Tor Vergata
Not yet recruiting
Last update posted :
07/27/2021
Initiation :
09/01/2021
Primary completion :
11/01/2022
Completion :
01/31/2023
CRP
Phase 1
BioEclipse Therapeutics
Recruiting
Last update posted :
07/27/2021
Initiation :
01/08/2021
Primary completion :
05/01/2022
Completion :
05/01/2022
HER-2 • ER • PGR
|
CRX100
Phase N/A
Emory University
Recruiting
Last update posted :
07/23/2021
Initiation :
06/29/2021
Primary completion :
06/30/2024
Completion :
12/31/2024
CD68 • CRP
Phase 2
Asan Medical Center
Active, not recruiting
Last update posted :
07/21/2021
Initiation :
05/15/2019
Primary completion :
12/01/2021
Completion :
12/01/2023
PD-L1 • CD8 • PD-1 • CD34 • GZMB • CD31 • CD68 • FOXP3
|
CD31 expression
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin
Phase 2
UNICANCER
Recruiting
Last update posted :
07/21/2021
Initiation :
12/01/2016
Primary completion :
12/01/2023
Completion :
01/01/2024
KRAS
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
Tianjin Medical University Cancer Institute and...
Recruiting
Last update posted :
07/20/2021
Initiation :
06/01/2021
Primary completion :
12/01/2023
Completion :
12/01/2024
MSI • POLE • POLD1
|
MSI-H/dMMR
|
Baize’an (tislelizumab)
Phase 1/2
Yale University
Completed
Last update posted :
07/20/2021
Initiation :
10/31/2016
Primary completion :
06/02/2020
Completion :
06/02/2020
ALB
|
oxaliplatin • Lonsurf (trifluridine/tipiracil)
Phase 3
Canadian Cancer Trials Group
Recruiting
Last update posted :
07/14/2021
Initiation :
12/03/2008
Primary completion :
12/15/2029
Completion :
12/15/2030
CEACAM5
Phase 3
Royal Marsden NHS Foundation Trust
Active, not recruiting
Last update posted :
07/13/2021
Initiation :
08/31/2018
Primary completion :
01/05/2021
Completion :
01/05/2022
MLH1 • MSH6 • MSH2
|
MSI-H/dMMR
|
5-fluorouracil • Bavencio (avelumab)
Phase N/A
Instituto de Investigación Sanitaria Aragón
Not yet recruiting
Last update posted :
07/13/2021
Initiation :
11/01/2021
Primary completion :
12/30/2023
Completion :
12/15/2024
IL6 • TNFA • GDF15 • CRP
Phase 2
Ann-Sofie Backman
Not yet recruiting
Last update posted :
07/09/2021
Initiation :
08/09/2021
Primary completion :
10/15/2028
Completion :
10/15/2038
MLH1 • MSH6 • MSH2 • EPCAM
|
MSH2 mutation • MLH1 mutation
|
Pentasa oral (mesalazine oral)
Phase 1/2
Roswell Park Cancer Institute
Completed
Last update posted :
07/08/2021
Initiation :
05/08/2015
Primary completion :
11/01/2017
Completion :
05/18/2021
EGFR
|
RAS wild-type
|
capecitabine • nintedanib
Phase 2
Criterium, Inc.
Recruiting
Last update posted :
07/05/2021
Initiation :
12/02/2019
Primary completion :
09/01/2022
Completion :
12/01/2022
KRAS
|
KRAS exon 2 mutation • RAS wild-type • KRAS wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation • KRAS exon 2 wild-type
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
07/01/2021
Initiation :
08/01/2000
Primary completion :
06/28/2021
Completion :
06/28/2021
CDKN1A
|
oxaliplatin • irinotecan • dexamethasone
Phase 2
Grupo Espanol Multidisciplinario del Cancer Dig...
Active, not recruiting
Last update posted :
06/30/2021
Initiation :
11/08/2018
Primary completion :
11/30/2020
Completion :
11/30/2022
BRAF
|
RAS wild-type
|
5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
Phase 1/2
Institut du Cancer de Montpellier - Val d'Aurelle
Completed
Last update posted :
06/23/2021
Initiation :
02/01/2009
Primary completion :
02/01/2011
Completion :
02/01/2012
KRAS
|
KRAS mutation
|
Nexavar (sorafenib) • irinotecan
Phase 2
UNICANCER
Completed
Last update posted :
06/18/2021
Initiation :
02/01/2011
Primary completion :
12/01/2015
Completion :
01/01/2021
BRAF • KRAS
|
Erbitux (cetuximab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase N/A
University of Southern Denmark
Not yet recruiting
Last update posted :
06/16/2021
Initiation :
08/01/2021
Primary completion :
09/01/2022
Completion :
09/01/2022
IL6 • IFNG • TNFA • IL2 • IL10 • IL17A • CCL4 • IL1B • IL16
Phase 1a/1b
Pionyr Immunotherapeutics Inc.
Recruiting
Last update posted :
06/16/2021
Initiation :
10/29/2020
Primary completion :
10/28/2023
Completion :
10/28/2023
HER-2 • PD-L1
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • PY314
Phase 3
GERCOR - Multidisciplinary Oncology Cooperative...
Recruiting
Last update posted :
06/16/2021
Initiation :
10/30/2013
Primary completion :
06/01/2021
Completion :
06/01/2021
KRAS • NRAS
|
NRAS mutation • RAS wild-type • KRAS wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation • NRAS wild-type
|
Erbitux (cetuximab) • Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
Phase 2
Zealand University Hospital
Not yet recruiting
Last update posted :
06/15/2021
Initiation :
10/01/2021
Primary completion :
10/01/2023
Completion :
12/01/2023
CD8 • CD4
|
Pegasys (pegylated interferon α -2a)
Phase 2
National Cancer Centre, Singapore
Recruiting
Last update posted :
05/25/2021
Initiation :
06/12/2019
Primary completion :
01/01/2022
Completion :
01/01/2022
CD8 • IFNG • PTPRC
|
IFNG expression
|
Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin
Phase N/A
Boryung Pharmaceutical Co., Ltd
Enrolling by invitation
Last update posted :
05/25/2021
Initiation :
03/25/2020
Primary completion :
03/25/2023
Completion :
03/25/2025
BRAF
|
oxaliplatin
Phase N/A
Massive Bio, Inc.
Recruiting
Last update posted :
05/25/2021
Initiation :
01/01/2018
Primary completion :
06/01/2022
Completion :
12/01/2022
EGFR • HER-2 • BRAF • PD-L1 • KRAS • ALK • ER • TP53 • FLT3 • ABL1 • TMB • NRAS • BRCA1 • BRCA2 • PTEN • FGFR2 • NTRK1 • NTRK3 • BCL2 • ROS1 • IDH1 • NTRK2 • NPM1 • IDH2 • HRAS • STK11 • DNMT3A • PDGFRA • RB1 • JAK2 • ERBB3 • NF1 • AKT1 • POLE • MCL1 • CCND1 • PDGFRB • PBRM1 • KDR • BAP1 • BCL6 • PTCH1 • PD-1 • MAP2K2 • MDM2 • VEGFA • MSH6 • CDK4 • CTNNB1 • FBXW7 • MSH2 • ATRX • FGFR4 • WT1 • CLDN18 • TSC2 • ERBB4 • TSC1 • JAK1 • PD-L2 • RAF1 • MDM4 • POLD1 • CHEK2 • FANCA • CEBPA • JAK3 • RICTOR • AURKA • MSH3 • TGFBR2 • BRCA • CDK6 • CHEK1 • GATA6 • AKT2 • CCND3 • MAP3K1 • MYCL • PARP1 • CCND2 • CSF1R • GNAS • HDAC1 • PRDM1 • ZNF217 • CDKN1A • CLDN8 • ERCC4 • GATA3 • PARP2 • SDHA
|
FGFR2 fusion • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
Phase N/A
New Mexico Cancer Care Alliance
Completed
Last update posted :
05/18/2021
Initiation :
05/22/2012
Primary completion :
10/21/2019
Completion :
10/21/2019
BRAF • KRAS • PIK3CA
|
KRAS mutation • BRAF mutation • PIK3CA mutation
Phase 1/2
Intensity Therapeutics, Inc.
Recruiting
Last update posted :
05/12/2021
Initiation :
02/09/2017
Primary completion :
07/01/2022
Completion :
10/01/2023
MSI
|
Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine formulation with cell penetration enhancer (INT230-6)
Phase 1/2
David Bajor
Suspended
Last update posted :
05/06/2021
Initiation :
09/12/2016
Primary completion :
10/01/2021
Completion :
10/01/2021
PIK3CA
|
PIK3CA mutation
|
capecitabine • telaglenastat (CB-839)
Phase 2
Zealand University Hospital
Recruiting
Last update posted :
05/06/2021
Initiation :
07/10/2018
Primary completion :
12/01/2021
Completion :
01/01/2022
CD8 • CASP3
|
CD8 positive
|
metformin
Phase 1
Baxalta now part of Shire
Completed
Last update posted :
05/05/2021
Initiation :
06/14/2012
Primary completion :
07/28/2016
Completion :
07/28/2016
MIF
Phase 2
The First Affiliated Hospital with Nanjing Medi...
Not yet recruiting
Last update posted :
04/30/2021
Initiation :
05/01/2021
Primary completion :
06/01/2022
Completion :
04/30/2024
TMB • MSI
|
AiRuiKa (camrelizumab) • Elunate (fruquintinib)
Phase 2
Universitätsmedizin Mannheim
Completed
Last update posted :
04/30/2021
Initiation :
04/01/2011
Primary completion :
12/01/2016
Completion :
12/01/2016
KRAS
|
RAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • leucovorin calcium • doxycycline
Phase 
University of Copenhagen
Recruiting
Last update posted :
04/29/2021
Initiation :
02/15/2021
Primary completion :
12/31/2021
Completion :
12/31/2021
MSH2
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
04/27/2021
Initiation :
11/19/2004
Primary completion :
11/01/2022
Completion :
11/01/2022
FLT1 • CD133 • FLT4 • VEGFD • VEGFC
|
KDR expression • FLT1 expression
|
Avastin (bevacizumab) • oxaliplatin • irinotecan • dexamethasone
Phase N/A
University of Illinois at Chicago
Recruiting
Last update posted :
04/27/2021
Initiation :
08/01/2018
Primary completion :
01/01/2022
Completion :
08/01/2022
IL6 • TNFA • PARP1 • OGG1 • XRCC1 • CRP
Phase 
Hospital del Mar
Active, not recruiting
Last update posted :
04/20/2021
Initiation :
01/01/2017
Primary completion :
03/30/2020
Completion :
12/31/2021
VEGFA
Phase 1
Mark Evers
Recruiting
Last update posted :
04/19/2021
Initiation :
10/06/2017
Primary completion :
08/31/2022
Completion :
08/31/2022
BRAF • KRAS • TP53 • PIK3CA • MYC • CTNNB1 • BIRC5 • FASN
|
TVB-2640
Phase 1/2
Sun Yat-sen University
Recruiting
Last update posted :
04/14/2021
Initiation :
05/10/2019
Primary completion :
05/01/2021
Completion :
05/01/2022
MSI
|
MSI-H/dMMR
|
Tuoyi (toripalimab) • celecoxib oral
Phase 1
James Varani
Completed
Last update posted :
04/12/2021
Initiation :
04/01/2016
Primary completion :
03/01/2021
Completion :
03/01/2021
CDH1 • BIRC5 • CASP3
Phase 1
Wake Forest University Health Sciences
Active, not recruiting
Last update posted :
04/01/2021
Initiation :
01/06/2015
Primary completion :
02/19/2019
Completion :
08/01/2022
KRAS
|
RAS wild-type • KRAS wild-type
|
5-fluorouracil • Bylantra (devimistat)
Phase 1/2
Sellas Life Sciences Group
Recruiting
Last update posted :
03/17/2021
Initiation :
06/28/2019
Primary completion :
01/31/2024
Completion :
04/30/2024
HER-2 • KRAS • PGR • WT1 • MUC16 • BRCA
|
HER-2 negative • RAS wild-type • KRAS wild-type • BRCA mutation • PGR negative
|
Keytruda (pembrolizumab) • Zeltherva (galinpepimut-S) • hydroxyurea
Phase 1/2
University of California, San Francisco
Active, not recruiting
Last update posted :
03/16/2021
Initiation :
08/31/2020
Primary completion :
02/29/2024
Completion :
02/29/2024
BRAF
|
BRAF V600E • BRAF V600
|
Opdivo (nivolumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
Phase 2
Abramson Cancer Center of the University of Pen...
Completed
Last update posted :
03/11/2021
Initiation :
10/01/2009
Primary completion :
10/01/2019
Completion :
10/01/2019
HER-2 • BRAF • KRAS • ER • RB1 • CCND1 • CDK4 • CCND2
|
KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation
|
cisplatin • Ibrance (palbociclib)
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
03/10/2021
Initiation :
06/14/2016
Primary completion :
11/30/2017
Completion :
12/31/2021
TP53 • MSI • PD-1
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
Phase N/A
Ohio State University Comprehensive Cancer Center
Completed
Last update posted :
03/10/2021
Initiation :
09/01/2013
Primary completion :
12/31/2019
Completion :
12/31/2020
MSI
Phase 2
National Guard Health Affairs
Recruiting
Last update posted :
03/01/2021
Initiation :
02/21/2021
Primary completion :
02/01/2024
Completion :
02/01/2024
BRAF
|
RAS wild-type • BRAF wild-type
|
Vectibix (panitumumab) • Stivarga (regorafenib)
Phase 1
Barbara Ann Karmanos Cancer Institute
Active, not recruiting
Last update posted :
03/01/2021
Initiation :
08/17/2011
Primary completion :
10/19/2020
Completion :
12/01/2021
IL2RA • CD4
|
Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • EGFR bi-armed autologous activated T cells
Phase 2
Eastern Cooperative Oncology Group
Active, not recruiting
Last update posted :
02/25/2021
Initiation :
10/08/2010
Primary completion :
02/22/2021
Completion :
07/06/2022
KRAS
|
RAS wild-type
|
Erbitux (cetuximab) • Avastin (bevacizumab) • Cyramza (ramucirumab) • irinotecan
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
02/22/2021
Initiation :
10/14/2020
Primary completion :
01/31/2024
Completion :
01/31/2024
BRAF
|
Opdivo (nivolumab) • SX-682
Phase 1b
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Recruiting
Last update posted :
02/19/2021
Initiation :
01/01/2021
Primary completion :
06/01/2022
Completion :
01/01/2023
BRAF • MGMT
|
MGMT promoter methylation
|
Avastin (bevacizumab) • 5-fluorouracil • temozolomide • irinotecan • leucovorin calcium
Phase 3
University College, London
Recruiting
Last update posted :
02/19/2021
Initiation :
10/01/2015
Primary completion :
10/01/2026
Completion :
10/01/2026
HER-2 • ER
|
HER-2 positive • HR positive • ER positive • HER-2 negative • HR negative • ER negative
|
aspirin
Phase 1
John Strickler, M.D.
Completed
Last update posted :
02/12/2021
Initiation :
01/01/2014
Primary completion :
05/10/2018
Completion :
08/29/2018
KRAS • MET
|
MET amplification • RAS wild-type • KRAS wild-type
|
Vectibix (panitumumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase N/A
Case Comprehensive Cancer Center
Completed
Last update posted :
02/09/2021
Initiation :
04/01/2012
Primary completion :
08/11/2015
Completion :
08/11/2016
PTGS2
|
PTGS2 expression
Phase N/A
University Hospital, Antwerp
Recruiting
Last update posted :
02/03/2021
Initiation :
09/14/2020
Primary completion :
03/01/2022
Completion :
03/01/2022
BRAF
|
RAS wild-type • BRAF wild-type
|
Vectibix (panitumumab)
Phase N/A
Jagiellonian University
Completed
Last update posted :
02/01/2021
Initiation :
11/01/2017
Primary completion :
11/30/2018
Completion :
01/30/2019
CXCL8 • TNFA • CXCL12 • CXCL2 • CXCL1
Phase 1/2
National Cancer Institute (NCI)
Suspended
Last update posted :
01/29/2021
Initiation :
05/16/2019
Primary completion :
12/01/2027
Completion :
12/01/2028
EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS
|
PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL
Phase 1/2
National Cancer Institute (NCI)
Suspended
Last update posted :
01/29/2021
Initiation :
09/21/2017
Primary completion :
06/29/2027
Completion :
06/29/2028
KRAS • ALK • NRAS • HRAS
|
KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • NRAS G12V
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
Phase 2
GERCOR - Multidisciplinary Oncology Cooperative...
Active, not recruiting
Last update posted :
01/27/2021
Initiation :
12/04/2017
Primary completion :
02/21/2019
Completion :
12/01/2023
PD-L1 • MSI
|
PD-L1 expression • MSI-H/dMMR • RAS wild-type
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
01/26/2021
Initiation :
04/11/2018
Primary completion :
09/23/2021
Completion :
09/23/2021
BRAF • PIK3CA • PTEN
|
BRAF mutation • PIK3CA mutation • RAS wild-type • PIK3CA mutation + PTEN mutation • BRAF wild-type
|
Mekinist (trametinib) • Lonsurf (trifluridine/tipiracil)
Phase N/A
Cliniques universitaires Saint-Luc- Université ...
Completed
Last update posted :
01/22/2021
Initiation :
04/04/2017
Primary completion :
10/01/2019
Completion :
10/01/2019
CRP
Phase 2
Sun Yat-sen University
Recruiting
Last update posted :
01/20/2021
Initiation :
12/01/2020
Primary completion :
06/30/2021
Completion :
12/31/2022
MSI
|
MSI-H/dMMR
|
capecitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin
Phase 4
Zealand University Hospital
Completed
Last update posted :
01/15/2021
Initiation :
06/28/2018
Primary completion :
12/05/2020
Completion :
01/03/2021
IL6 • TNFA • GZMB • IL10 • IL17A • IL18 • IL1B • IL22
|
morphine sulphate • paracetamol • ropivacaine
Phase 3
Xiyuan Hospital of China Academy of Chinese Med...
Recruiting
Last update posted :
01/12/2021
Initiation :
12/12/2018
Primary completion :
05/31/2021
Completion :
05/31/2021
MSI
|
MSI-H/dMMR
Phase 2
Southwest Oncology Group
Completed
Last update posted :
12/30/2020
Initiation :
11/01/2014
Primary completion :
11/13/2017
Completion :
11/19/2020
EGFR • BRAF • KRAS • NRAS • UGT1A1
|
BRAF V600E • BRAF V600 • UGT1A1*1*1
|
Erbitux (cetuximab) • Zelboraf (vemurafenib) • irinotecan
Phase 2
Renmin Hospital of Wuhan University
Recruiting
Last update posted :
12/24/2020
Initiation :
12/20/2019
Primary completion :
11/30/2024
Completion :
11/30/2025
CRP
Phase 1a
Novita Pharmaceuticals, Inc.
Completed
Last update posted :
12/22/2020
Initiation :
12/21/2017
Primary completion :
05/07/2020
Completion :
05/07/2020
ALB
|
NP-G2-044
Phase N/A
Texas A&M University
Completed
Last update posted :
12/18/2020
Initiation :
01/01/2012
Primary completion :
12/01/2017
Completion :
12/01/2017
CDKN1A
Phase 1/2
Menarini Group
Recruiting
Last update posted :
12/07/2020
Initiation :
07/20/2020
Primary completion :
07/01/2023
Completion :
07/01/2023
BRAF • KRAS • PIK3CA
|
BRAF mutation • PIK3CA mutation • BRAF wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • MEN1611
Phase 3
Institut für Klinische Krebsforschung IKF GmbH ...
Recruiting
Last update posted :
11/17/2020
Initiation :
01/24/2019
Primary completion :
12/01/2023
Completion :
06/01/2024
BRAF
|
BRAF V600E • BRAF V600
|
Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil)
Phase 3
Taiho Pharmaceutical Co., Ltd.
Completed
Last update posted :
11/17/2020
Initiation :
09/01/2013
Primary completion :
02/16/2016
Completion :
06/30/2016
KRAS
|
KRAS mutation • RAS wild-type • KRAS wild-type
|
Lonsurf (trifluridine/tipiracil)
Phase 2
Federation Francophone de Cancerologie Digestive
Completed
Last update posted :
11/09/2020
Initiation :
01/01/2007
Primary completion :
01/01/2008
Completion :
12/01/2008
UGT1A1
|
UGT1A1*28 • UGT1A1*1*1
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium
Phase 3
Federation Francophone de Cancerologie Digestive
Completed
Last update posted :
11/09/2020
Initiation :
11/01/2005
Primary completion :
11/01/2009
Completion :
06/22/2010
KRAS • CEACAM5
|
RAS wild-type • KRAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • leucovorin calcium
Phase N/A
Aarhus University Hospital
Recruiting
Last update posted :
11/03/2020
Initiation :
11/01/2020
Primary completion :
07/31/2023
Completion :
09/30/2028
BRAF
Phase 2
Cliniques universitaires Saint-Luc- Université ...
Completed
Last update posted :
10/22/2020
Initiation :
05/01/2013
Primary completion :
05/01/2019
Completion :
05/01/2019
KRAS
|
KRAS mutation • KRAS wild-type
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
Grupo Espanol Multidisciplinario del Cancer Dig...
Not yet recruiting
Last update posted :
10/20/2020
Initiation :
01/01/2021
Primary completion :
01/01/2023
Completion :
01/01/2025
ALB
|
Avastin (bevacizumab) • oxaliplatin • irinotecan • leucovorin calcium • DC Bead (E7040)
Phase 1b/2a
Esperas Pharma Inc.
Recruiting
Last update posted :
09/16/2020
Initiation :
05/01/2016
Primary completion :
03/27/2020
Completion :
06/01/2021
HER-2 • ER • PGR
|
HER-2 negative • ER expression
|
gemcitabine • ESP-01
Phase N/A
Albert Einstein College of Medicine
Completed
Last update posted :
09/16/2020
Initiation :
02/01/2008
Primary completion :
12/01/2018
Completion :
12/01/2018
ERCC1
|
oxaliplatin
Phase 3
Sahlgrenska University Hospital, Sweden
Recruiting
Last update posted :
09/15/2020
Initiation :
09/02/2020
Primary completion :
12/31/2021
Completion :
12/31/2022
CRP
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Completed
Last update posted :
09/15/2020
Initiation :
05/01/2015
Primary completion :
12/01/2018
Completion :
12/01/2018
IGF1 • IGFBP3
|
metformin
Phase 2
King Abdullah Medical City
Recruiting
Last update posted :
09/11/2020
Initiation :
06/10/2020
Primary completion :
07/01/2022
Completion :
07/01/2022
KRAS
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
09/09/2020
Initiation :
01/31/2018
Primary completion :
05/22/2018
Completion :
08/24/2020
CEACAM5
|
ETBX-011 • ETBX-051 • ETBX-061
Phase 2
Asan Medical Center
Active, not recruiting
Last update posted :
08/28/2020
Initiation :
04/12/2018
Primary completion :
03/31/2022
Completion :
05/31/2022
POLE • MLH1 • MSH6 • MSH2
|
MSI-H/dMMR • POLE mutation
|
Imfinzi (durvalumab)
Phase 3
Fudan University
Not yet recruiting
Last update posted :
08/25/2020
Initiation :
10/01/2020
Primary completion :
10/01/2022
Completion :
11/01/2022
BRAF
|
BRAF wild-type
|
Erbitux (cetuximab) • Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium
Phase N/A
Northumbria University
Active, not recruiting
Last update posted :
08/20/2020
Initiation :
09/23/2019
Primary completion :
03/06/2020
Completion :
09/30/2020
IL6 • IGF1
Phase 1
Advaxis, Inc.
Active, not recruiting
Last update posted :
08/11/2020
Initiation :
06/07/2018
Primary completion :
01/31/2022
Completion :
01/31/2022
EGFR
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • ADXS-NEO
Phase 2
Eli Lilly and Company
Completed
Last update posted :
08/06/2020
Initiation :
08/01/2005
Primary completion :
03/01/2008
Completion :
03/01/2008
CEACAM5
|
Kinenza (enzastaurin)
Phase 2
Fudan University
Active, not recruiting
Last update posted :
08/05/2020
Initiation :
01/01/2019
Primary completion :
08/01/2020
Completion :
12/01/2020
UGT1A1
|
UGT1A1*28 • UGT1A1*1*1
|
irinotecan • Tomudex (raltitrexed)
Phase N/A
Cyprus University of Technology
Active, not recruiting
Last update posted :
07/30/2020
Initiation :
01/01/2019
Primary completion :
01/01/2021
Completion :
05/01/2021
EGFR
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
07/28/2020
Initiation :
07/14/2014
Primary completion :
03/31/2021
Completion :
05/31/2021
ALB
Phase 2
EpicentRx, Inc.
Active, not recruiting
Last update posted :
07/22/2020
Initiation :
05/01/2014
Primary completion :
12/01/2020
Completion :
12/01/2020
KRAS
|
RAS wild-type • KRAS wild-type
|
Avastin (bevacizumab) • irinotecan • Stivarga (regorafenib) • RRx-001
Phase 1
Asana BioSciences
Completed
Last update posted :
07/09/2020
Initiation :
01/19/2018
Primary completion :
06/30/2020
Completion :
06/30/2020
KRAS • HRAS
|
KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation
|
ASN007
Phase 3
UNICANCER
Recruiting
Last update posted :
06/25/2020
Initiation :
03/27/2017
Primary completion :
06/01/2024
Completion :
06/01/2026
CEACAM5
|
5-fluorouracil • oxaliplatin • irinotecan
Phase 1
UNC Lineberger Comprehensive Cancer Center
Completed
Last update posted :
06/22/2020
Initiation :
06/01/2013
Primary completion :
10/05/2016
Completion :
10/05/2016
EGFR • CEACAM5
|
irinotecan
Phase 2
Translational Research Center for Medical Innov...
Completed
Last update posted :
06/17/2020
Initiation :
05/21/2015
Primary completion :
06/01/2019
Completion :
06/01/2019
UGT1A1
|
UGT1A1*1*1
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Levofolinate
Phase 1
Gilead Sciences
Completed
Last update posted :
06/02/2020
Initiation :
03/29/2013
Primary completion :
04/23/2019
Completion :
04/23/2019
HER-2 • ALK • EML4
|
EGFR mutation • HER-2 negative • EML4-ALK fusion • ALK fusion • ALK translocation
|
Avastin (bevacizumab) • carboplatin • gemcitabine • 5-fluorouracil • Abraxane (albumin-bound paclitaxel) • oxaliplatin • irinotecan • pemetrexed • leucovorin calcium • andecaliximab (GS-5745)
Phase 2
Joanne Jeter
Active, not recruiting
Last update posted :
05/15/2020
Initiation :
08/21/2018
Primary completion :
12/31/2020
Completion :
12/31/2020
MLH1 • MSH2
|
MSH2 mutation • MLH1 mutation
|
Opdivo (nivolumab)
Phase 2
The First Affiliated Hospital of Xiamen University
Recruiting
Last update posted :
05/15/2020
Initiation :
03/04/2020
Primary completion :
03/04/2021
Completion :
03/04/2021
MSI
|
MSI-H/dMMR
|
capecitabine • Tuoyi (toripalimab) • oxaliplatin
Phase 3
National Cancer Institute (NCI)
Completed
Last update posted :
05/13/2020
Initiation :
02/01/2004
Primary completion :
11/01/2012
Completion :
11/01/2012
KRAS
|
KRAS mutation • RAS wild-type • KRAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 3
Alliance for Clinical Trials in Oncology
Completed
Last update posted :
05/07/2020
Initiation :
11/01/2005
Primary completion :
02/01/2015
Completion :
01/01/2018
KRAS • UGT1A1
|
RAS wild-type • UGT1A1*28 • UGT1A1*1*1
|
Erbitux (cetuximab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 1
Millennium Pharmaceuticals, Inc.
Completed
Last update posted :
04/22/2020
Initiation :
04/23/2018
Primary completion :
02/27/2020
Completion :
02/27/2020
ALB
|
TAK-164
Phase 2
Celgene
Completed
Last update posted :
04/21/2020
Initiation :
05/05/2014
Primary completion :
11/10/2014
Completion :
01/09/2015
KRAS • NRAS
|
KRAS mutation • NRAS mutation • RAS wild-type
|
Abraxane (albumin-bound paclitaxel)
Phase 2
Imperial College London
Completed
Last update posted :
04/21/2020
Initiation :
09/17/2012
Primary completion :
02/22/2019
Completion :
02/22/2019
ALB
|
Inlyta (axitinib)
Phase N/A
Abramson Cancer Center of the University of Pen...
Completed
Last update posted :
04/09/2020
Initiation :
12/01/2015
Primary completion :
01/01/2016
Completion :
01/15/2016
ICAM1
Phase 3
Shanghai General Hospital, Shanghai Jiao Tong U...
Not yet recruiting
Last update posted :
04/08/2020
Initiation :
08/01/2020
Primary completion :
01/01/2022
Completion :
01/01/2025
MSI
|
5-fluorouracil • capecitabine • leucovorin calcium
Phase 2
Asan Medical Center
Active, not recruiting
Last update posted :
04/03/2020
Initiation :
05/22/2017
Primary completion :
07/31/2021
Completion :
12/31/2021
POLE • MLH1 • MSH6 • MSH2
|
MSI-H/dMMR • POLE mutation
|
Bavencio (avelumab)
Phase 
Lille Catholic University
Not yet recruiting
Last update posted :
04/03/2020
Initiation :
06/30/2020
Primary completion :
06/30/2023
Completion :
12/30/2023
CD19 • CD8 • CD4
Phase 2
NYU Langone Health
Completed
Last update posted :
04/03/2020
Initiation :
06/01/2004
Primary completion :
08/01/2012
Completion :
06/01/2015
EGFR • KRAS
|
KRAS mutation • EGFR expression • RAS wild-type • KRAS wild-type
|
Erbitux (cetuximab) • capecitabine • oxaliplatin
Phase 2
Sun Yat-sen University
Completed
Last update posted :
03/31/2020
Initiation :
02/01/2014
Primary completion :
12/01/2019
Completion :
12/01/2019
KRAS • NRAS
|
RAS wild-type • KRAS wild-type • NRAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
Federation Francophone de Cancerologie Digestive
Completed
Last update posted :
03/30/2020
Initiation :
11/01/2007
Primary completion :
09/01/2013
Completion :
12/01/2013
UGT1A1
|
UGT1A1*28 • UGT1A1*1*1
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Neupogen (filgrastim)
Phase N/A
Universidad de Costa Rica
Active, not recruiting
Last update posted :
03/26/2020
Initiation :
01/16/2019
Primary completion :
10/01/2021
Completion :
10/01/2021
MTHFR
|
MTHFR C677T
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
03/13/2020
Initiation :
02/10/2011
Primary completion :
01/29/2014
Completion :
01/29/2014
EGFR • KRAS
|
RAS wild-type • KRAS wild-type
|
Erbitux (cetuximab) • lenalidomide • KL 140 (cetuximab biosimilar)
Phase 3
Beijing Cancer Hospital
Recruiting
Last update posted :
03/06/2020
Initiation :
06/01/2017
Primary completion :
07/31/2021
Completion :
07/31/2024
MSI
|
capecitabine • oxaliplatin
Phase 2b
The Rogosin Institute
Completed
Last update posted :
03/05/2020
Initiation :
01/01/2014
Primary completion :
03/01/2019
Completion :
03/01/2019
Cancer antigen 19-9
Phase 1/2
howard safran
Completed
Last update posted :
02/17/2020
Initiation :
05/01/2012
Primary completion :
03/01/2015
Completion :
07/01/2015
EGFR • KRAS
|
KRAS mutation • RAS wild-type • KRAS wild-type
|
Erbitux (cetuximab) • Halaven (eribulin mesylate)
Phase 4
Jessa Hospital
Not yet recruiting
Last update posted :
02/13/2020
Initiation :
02/18/2020
Primary completion :
09/30/2021
Completion :
09/30/2021
DPYD
|
DPYD wild-type
|
5-fluorouracil • capecitabine
Phase 3
Massachusetts General Hospital
Recruiting
Last update posted :
02/13/2020
Initiation :
01/20/2020
Primary completion :
02/01/2022
Completion :
02/01/2023
BRAF • MSI • MLH1 • MSH6 • MSH2
|
BRAF V600E • MSI-H/dMMR • BRAF V600 • MSH6 expression
|
Opdivo (nivolumab) • Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • Braftovi (encorafenib) • irinotecan • leucovorin calcium
Phase 3
Sun Yat-sen University
Not yet recruiting
Last update posted :
02/10/2020
Initiation :
09/01/2020
Primary completion :
12/30/2023
Completion :
03/30/2024
BRAF
|
BRAF mutation • BRAF wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • capecitabine • leucovorin calcium
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Completed
Last update posted :
02/06/2020
Initiation :
09/01/2013
Primary completion :
08/01/2019
Completion :
08/01/2019
MSI
|
Keytruda (pembrolizumab)
Phase N/A
CHANGHEE LEE
Completed
Last update posted :
01/31/2020
Initiation :
09/01/2016
Primary completion :
09/01/2016
Completion :
09/01/2016
BCL2
Phase N/A
University of Michigan
Completed
Last update posted :
01/15/2020
Initiation :
10/01/2011
Primary completion :
04/01/2019
Completion :
04/01/2019
IKZF1 • VIM • BCAT1
Phase N/A
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
01/07/2020
Initiation :
09/01/1994
Primary completion :
09/30/2020
Completion :
09/30/2020
MSH2
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
12/17/2019
Initiation :
01/07/2011
Primary completion :
08/27/2013
Completion :
08/27/2013
KRAS
|
KRAS mutation
|
Erbitux (cetuximab) • Koselugo (selumetinib)
Phase 2
Dana-Farber Cancer Institute
Completed
Last update posted :
12/16/2019
Initiation :
04/13/2012
Primary completion :
11/09/2019
Completion :
11/09/2019
KRAS
|
KRAS mutation • RAS wild-type • KRAS wild-type
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
Phase N/A
The First Affiliated Hospital of Dalian Medical...
Recruiting
Last update posted :
12/13/2019
Initiation :
12/20/2019
Primary completion :
12/20/2020
Completion :
05/01/2021
IL6 • TNFA • CD4
|
5-fluorouracil • capecitabine • oxaliplatin
Phase N/A
Yonsei University
Completed
Last update posted :
12/04/2019
Initiation :
12/01/2017
Primary completion :
05/27/2019
Completion :
05/27/2019
IL6
|
dexmedetomidine
Phase 2
Chinese PLA General Hospital
Recruiting
Last update posted :
11/26/2019
Initiation :
08/28/2019
Primary completion :
03/01/2020
Completion :
05/01/2020
KRAS
|
RAS wild-type • KRAS wild-type
|
Tyvyt (sintilimab) • Elunate (fruquintinib)
Phase N/A
University of Pisa
Completed
Last update posted :
11/25/2019
Initiation :
03/01/2017
Primary completion :
06/01/2018
Completion :
03/30/2019
BRAF • PD-L1 • FGFR1 • CD8 • IL6 • PD-1 • VEGFA • LAG3 • TNFA • IL2 • CCL2 • TGFB1 • CD4 • CD68 • NLRP3
Phase N/A
University of Wisconsin, Madison
Completed
Last update posted :
11/18/2019
Initiation :
07/01/2016
Primary completion :
01/24/2018
Completion :
01/24/2018
HER-2
Phase N/A
Ain Shams University
Recruiting
Last update posted :
11/05/2019
Initiation :
10/01/2019
Primary completion :
09/30/2020
Completion :
09/30/2020
TNFA
|
5-fluorouracil • atorvastatin
Phase 3
University Hospital, Rouen
Recruiting
Last update posted :
10/24/2019
Initiation :
07/12/2018
Primary completion :
07/01/2024
Completion :
07/01/2024
PI3K
|
aspirin
Phase N/A
Auburn University
Completed
Last update posted :
10/15/2019
Initiation :
07/23/2018
Primary completion :
12/12/2018
Completion :
12/12/2018
IL6 • TNFA • CRP
Phase 2
Universitaire Ziekenhuizen Leuven
Completed
Last update posted :
10/11/2019
Initiation :
12/01/2010
Primary completion :
06/01/2016
Completion :
07/01/2019
KRAS
|
RAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • leucovorin calcium
Phase 1
The University of The West Indies
Recruiting
Last update posted :
10/08/2019
Initiation :
10/01/2018
Primary completion :
09/30/2020
Completion :
09/30/2020
CEACAM5
Phase N/A
Instituto de Investigación Marqués de Valdecilla
Recruiting
Last update posted :
09/25/2019
Initiation :
11/01/2018
Primary completion :
06/01/2021
Completion :
12/01/2021
CRP
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
09/20/2019
Initiation :
03/01/2013
Primary completion :
06/01/2015
Completion :
08/05/2015
BRAF • KRAS • PIK3CA • PTEN
|
BRAF mutation • PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA expression
|
MK-2206
Phase N/A
Cliniques universitaires Saint-Luc- Université ...
Recruiting
Last update posted :
09/18/2019
Initiation :
04/04/2017
Primary completion :
04/01/2020
Completion :
07/01/2020
CRP
Phase 2
Sun Yat-sen University
Recruiting
Last update posted :
09/17/2019
Initiation :
07/19/2019
Primary completion :
07/19/2020
Completion :
07/19/2020
KRAS
|
RAS wild-type • KRAS wild-type
|
Opdivo (nivolumab) • irinotecan • Stivarga (regorafenib)
Phase 2
British Columbia Cancer Agency
Completed
Last update posted :
09/12/2019
Initiation :
08/01/2016
Primary completion :
03/01/2018
Completion :
11/07/2018
KRAS
|
RAS wild-type • KRAS wild-type
|
Stivarga (regorafenib) • erbumine (LY3295668) • perindopril arginine
Phase N/A
University of Pennsylvania
Completed
Last update posted :
08/28/2019
Initiation :
07/01/2014
Primary completion :
08/01/2019
Completion :
08/01/2019
SEPTIN9
Phase 2
Amgen
Completed
Last update posted :
08/21/2019
Initiation :
04/24/2009
Primary completion :
05/30/2012
Completion :
07/07/2016
BRAF • KRAS
|
RAS wild-type • KRAS wild-type • BRAF wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab) • oxaliplatin
Phase 1
Sidney Kimmel Comprehensive Cancer Center at Jo...
Completed
Last update posted :
08/14/2019
Initiation :
03/01/2008
Primary completion :
08/01/2011
Completion :
01/01/2013
IFNG • EPCAM
|
cyclophosphamide
Phase 1/2
National Taiwan University Hospital
Not yet recruiting
Last update posted :
07/29/2019
Initiation :
01/01/2020
Primary completion :
12/31/2021
Completion :
06/30/2022
BRAF • KRAS
|
KRAS mutation • BRAF mutation
Phase N/A
Assistance Publique - Hôpitaux de Paris
Recruiting
Last update posted :
07/02/2019
Initiation :
04/05/2018
Primary completion :
02/01/2021
Completion :
02/01/2021
BRAF
Phase 3
Bayer
No Longer Available
Last update posted :
05/29/2019
KRAS
|
RAS wild-type • KRAS wild-type
|
Stivarga (regorafenib)
Phase N/A
Samsung Medical Center
Active, not recruiting
Last update posted :
05/20/2019
Initiation :
05/24/2011
Primary completion :
12/01/2019
Completion :
04/01/2020
ERCC1 • GSTP1 • XRCC1
|
5-fluorouracil • leucovorin calcium
Phase 3
Bayer
Completed
Last update posted :
04/22/2019
Initiation :
07/24/2013
Primary completion :
04/24/2015
Completion :
06/11/2018
KRAS
|
RAS wild-type • KRAS wild-type
|
Stivarga (regorafenib)
Phase 2
Spanish Cooperative Group for the Treatment of ...
Completed
Last update posted :
04/11/2019
Initiation :
07/01/2012
Primary completion :
11/01/2018
Completion :
11/01/2018
BRAF
|
RAS wild-type
|
Erbitux (cetuximab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 3
Spanish Cooperative Group for the Treatment of ...
Completed
Last update posted :
04/11/2019
Initiation :
07/01/2012
Primary completion :
11/01/2018
Completion :
11/01/2018
BRAF • PI3K
|
BRAF mutation
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
Phase 2
John Hays
Active, not recruiting
Last update posted :
03/27/2019
Initiation :
02/01/2013
Primary completion :
12/31/2019
Completion :
12/31/2019
KRAS
|
KRAS mutation • NRAS mutation
|
Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
Phase 1/2
Centre Georges Francois Leclerc
Recruiting
Last update posted :
03/15/2019
Initiation :
11/07/2018
Primary completion :
01/07/2023
Completion :
01/07/2023
ALB
|
Avastin (bevacizumab)
Phase N/A
Assistance Publique - Hôpitaux de Paris
Recruiting
Last update posted :
03/14/2019
Initiation :
02/05/2019
Primary completion :
08/01/2019
Completion :
08/01/2019
BRAF • MSI
Phase 4
The Institute of Molecular and Translational Me...
Completed
Last update posted :
03/13/2019
Initiation :
01/01/2015
Primary completion :
03/01/2019
Completion :
03/01/2019
CEACAM5
|
morphine sulphate
Phase N/A
Alliance for Clinical Trials in Oncology
Completed
Last update posted :
02/19/2019
Initiation :
07/01/2007
Primary completion :
02/01/2019
Completion :
02/01/2019
BRAF • PIK3CA • MSI • MLH1 • MRE11A • FASN • WRN
Phase 2
Ente Ospedaliero Ospedali Galliera
Recruiting
Last update posted :
02/15/2019
Initiation :
03/15/2017
Primary completion :
09/15/2019
Completion :
03/15/2020
IL6 • CTNNB1 • RELA • PI3K
|
metformin • aspirin
Phase 3
Cinnagen
Recruiting
Last update posted :
02/06/2019
Initiation :
01/20/2018
Primary completion :
11/30/2019
Completion :
02/01/2020
EGFR
|
EGFR expression • RAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • cetuximab biosimilar
Phase N/A
Centre Hospitalier Universitaire de Nīmes
Completed
Last update posted :
01/24/2019
Initiation :
01/22/2018
Primary completion :
11/11/2018
Completion :
11/11/2018
BRAF • KRAS
|
BRAF V600E • KRAS mutation • BRAF V600
Phase 4
Hoffmann-La Roche
Completed
Last update posted :
01/21/2019
Initiation :
06/26/2012
Primary completion :
09/15/2016
Completion :
09/30/2016
CEACAM5
|
Avastin (bevacizumab) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
Phase N/A
University of Arizona
Completed
Last update posted :
01/04/2019
Initiation :
10/17/2014
Primary completion :
11/01/2018
Completion :
11/01/2018
EGFR • BRAF
Phase 1
WntResearch AB
Completed
Last update posted :
12/28/2018
Initiation :
04/01/2016
Primary completion :
10/01/2017
Completion :
10/01/2017
WNT5A
|
Foxy-5
Phase 3
Amgen
Completed
Last update posted :
12/25/2018
Initiation :
02/02/2010
Primary completion :
02/05/2013
Completion :
03/07/2017
KRAS
|
RAS wild-type • KRAS wild-type
|
Erbitux (cetuximab) • Vectibix (panitumumab)
Phase 1
Oncolytics Biotech
Completed
Last update posted :
12/19/2018
Initiation :
12/01/2010
Primary completion :
02/01/2018
Completion :
11/01/2018
KRAS
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Reolysin (pelareorep)
Phase 1
Eli Lilly and Company
Completed
Last update posted :
12/14/2018
Initiation :
08/10/2016
Primary completion :
05/15/2017
Completion :
05/15/2017
BRAF • KRAS
|
KRAS mutation • BRAF mutation
|
prexasertib (LY2606368) • ralimetinib (LY 2228820)
Phase 1b/2
Syndax Pharmaceuticals
Active, not recruiting
Last update posted :
11/28/2018
Initiation :
07/01/2015
Primary completion :
08/01/2019
Completion :
08/01/2019
EGFR • BRAF • PD-L1 • ALK • MSI
|
EGFR mutation • BRAF mutation • BRAF V600 • ALK positive • ALK rearrangement • EGFR rearrangement
|
Keytruda (pembrolizumab) • entinostat (SNDX-275)
Phase 2
University of California, Irvine
Completed
Last update posted :
10/31/2018
Initiation :
04/01/2003
Primary completion :
01/01/2007
Completion :
01/01/2007
CSF2
Phase 2
Fondazione del Piemonte per l'Oncologia
Active, not recruiting
Last update posted :
10/30/2018
Initiation :
08/01/2012
Primary completion :
12/01/2018
Completion :
06/01/2019
KRAS
|
KRAS exon 2 mutation • RAS wild-type • KRAS wild-type • NRAS wild-type
|
lapatinib • Kadcyla (ado-trastuzumab emtansine) • Perjeta (pertuzumab)
Phase 2
Amgen
Completed
Last update posted :
10/17/2018
Initiation :
11/01/2006
Primary completion :
05/10/2012
Completion :
04/01/2013
KRAS
|
RAS wild-type • KRAS wild-type
|
Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
Phase 2
University of Leeds
Recruiting
Last update posted :
10/15/2018
Initiation :
02/14/2018
Primary completion :
02/14/2019
Completion :
03/14/2019
MET
|
MET expression
Phase N/A
The University of Texas Health Science Center a...
Withdrawn
Last update posted :
09/17/2018
Initiation :
01/20/2017
Primary completion :
09/12/2018
Completion :
09/12/2018
PD-L1
Phase 
Centre Oscar Lambret
Active, not recruiting
Last update posted :
09/12/2018
Initiation :
01/31/2018
Primary completion :
10/01/2019
Completion :
10/01/2019
BRCA1 • BRCA2 • BRCA
|
BRCA2 mutation • BRCA mutation
Phase 2
The Netherlands Cancer Institute
Recruiting
Last update posted :
08/27/2018
Initiation :
03/01/2018
Primary completion :
12/01/2019
Completion :
03/01/2020
BRAF • KRAS
|
KRAS mutation • BRAF mutation • BRAF wild-type
|
vinorelbine tartrate
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
08/24/2018
Initiation :
10/01/2006
Primary completion :
09/01/2012
Completion :
09/01/2012
EGFR
|
Zaltrap (ziv-aflibercept IV)
Phase 4
Medical Center Alkmaar
Completed
Last update posted :
07/31/2018
Initiation :
10/01/2014
Primary completion :
06/01/2016
Completion :
06/01/2016
IL6 • TNFA • IL10
|
Omegaven (omega-3 long-chain polyunsaturated fatty acids)
Phase N/A
UNC Lineberger Comprehensive Cancer Center
Completed
Last update posted :
07/25/2018
Initiation :
04/01/2009
Primary completion :
08/18/2014
Completion :
01/28/2016
AFP • CEACAM5
Phase 2
SCRI Development Innovations, LLC
Completed
Last update posted :
07/12/2018
Initiation :
07/01/2014
Primary completion :
06/04/2017
Completion :
06/04/2017
KRAS
|
RAS wild-type • KRAS wild-type
|
Stivarga (regorafenib) • SIR-Spheres (yttrium-90 microspheres)
Phase 2
Grupo Espanol Multidisciplinario del Cancer Dig...
Completed
Last update posted :
05/16/2018
Initiation :
11/08/2010
Primary completion :
02/13/2015
Completion :
02/13/2015
KRAS • MMP7
|
RAS wild-type • KRAS wild-type
|
5-fluorouracil • Vectibix (panitumumab) • leucovorin calcium
Phase N/A
Zealand University Hospital
Completed
Last update posted :
03/22/2018
Initiation :
01/01/2016
Primary completion :
12/01/2017
Completion :
12/01/2017
TP53 • IL6 • TNFA • IL2 • TGFB1 • FOXO3 • IL10 • IL1B
|
ATM expression
Phase N/A
University of Edinburgh
Not yet recruiting
Last update posted :
03/20/2018
Initiation :
04/01/2018
Primary completion :
10/31/2018
Completion :
11/30/2018
HER-2 • ER • PGR
Phase N/A
Odense University Hospital
Enrolling by invitation
Last update posted :
02/23/2018
Initiation :
05/12/2017
Primary completion :
02/01/2019
Completion :
02/01/2019
KRAS
Phase 4
Grupo Espanol Multidisciplinario del Cancer Dig...
Completed
Last update posted :
02/16/2018
Initiation :
11/16/2011
Primary completion :
12/08/2014
Completion :
12/18/2017
KRAS
|
KRAS mutation
|
Avastin (bevacizumab) • capecitabine • oxaliplatin
Phase 2
Prof. Dr. Carl Schimanski
Completed
Last update posted :
02/13/2018
Initiation :
08/01/2011
Primary completion :
12/31/2017
Completion :
01/31/2018
MUC1
|
Stimuvax (tecemotide)
Phase 2
PharmaMar
Active, not recruiting
Last update posted :
02/09/2018
Initiation :
01/10/2018
Primary completion :
10/01/2019
Completion :
10/01/2019
BRAF
|
BRAF mutation
|
plocabulin (PM184)
Phase 3
Sichuan Kelun Pharmaceutical Research Institute...
Recruiting
Last update posted :
02/08/2018
Initiation :
02/01/2018
Primary completion :
12/01/2020
Completion :
12/01/2023
BRAF
|
BRAF V600E • BRAF V600 • RAS wild-type • BRAF wild-type • BRAF V600 wild-type
|
oxaliplatin • KL 140 (cetuximab biosimilar)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/29/2018
Initiation :
01/05/2012
Primary completion :
03/03/2016
Completion :
09/01/2016
CD8 • TNFA • IL2 • CD27 • CD4 • CD40LG • LAMP1
|
ER positive • CD8 expression
|
GI-6301